Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Raised to $45.00 at Piper Sandler

Day One Biopharmaceuticals (NASDAQ:DAWNGet Rating) had its price target raised by Piper Sandler from $40.00 to $45.00 in a research note issued to investors on Sunday, The Fly reports.

Several other brokerages have also recently commented on DAWN. The Goldman Sachs Group initiated coverage on Day One Biopharmaceuticals in a research note on Monday, December 5th. They issued a buy rating and a $45.00 price target for the company. Bank of America initiated coverage on Day One Biopharmaceuticals in a research note on Thursday, December 1st. They issued a buy rating and a $34.00 price target for the company. Needham & Company LLC initiated coverage on Day One Biopharmaceuticals in a research note on Wednesday, December 14th. They issued a buy rating and a $40.00 price target for the company. Finally, HC Wainwright initiated coverage on Day One Biopharmaceuticals in a research note on Thursday, December 15th. They issued a buy rating and a $35.00 price target for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Day One Biopharmaceuticals currently has a consensus rating of Buy and an average price target of $39.00.

Day One Biopharmaceuticals Trading Up 0.9 %

Shares of DAWN opened at $21.34 on Friday. Day One Biopharmaceuticals has a fifty-two week low of $5.44 and a fifty-two week high of $28.35. The business’s 50-day moving average is $20.73 and its 200-day moving average is $20.76.

Day One Biopharmaceuticals (NASDAQ:DAWNGet Rating) last issued its earnings results on Monday, November 7th. The company reported ($0.53) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.53). Sell-side analysts predict that Day One Biopharmaceuticals will post -2.18 EPS for the current fiscal year.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 1st. The stock was sold at an average price of $20.03, for a total transaction of $200,300.00. Following the completion of the sale, the chief financial officer now owns 294,401 shares of the company’s stock, valued at $5,896,852.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Julie Papanek Grant sold 25,000 shares of the stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $20.65, for a total value of $516,250.00. Following the completion of the sale, the director now directly owns 380,000 shares of the company’s stock, valued at $7,847,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Charles N. York II sold 10,000 shares of the stock in a transaction that occurred on Tuesday, November 1st. The shares were sold at an average price of $20.03, for a total value of $200,300.00. Following the completion of the sale, the chief financial officer now directly owns 294,401 shares of the company’s stock, valued at $5,896,852.03. The disclosure for this sale can be found here. Insiders sold 119,178 shares of company stock valued at $2,458,187 over the last 90 days. 8.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several hedge funds have recently modified their holdings of DAWN. Amalgamated Bank bought a new stake in shares of Day One Biopharmaceuticals in the first quarter valued at approximately $30,000. ACG Wealth acquired a new position in shares of Day One Biopharmaceuticals in the second quarter valued at $32,000. TCI Wealth Advisors Inc. acquired a new position in shares of Day One Biopharmaceuticals in the second quarter valued at $35,000. Quantbot Technologies LP acquired a new position in shares of Day One Biopharmaceuticals in the second quarter valued at $51,000. Finally, UBS Group AG acquired a new position in shares of Day One Biopharmaceuticals in the second quarter valued at $69,000. 86.08% of the stock is owned by institutional investors.

Day One Biopharmaceuticals Company Profile

(Get Rating)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

See Also

The Fly logo

Analyst Recommendations for Day One Biopharmaceuticals (NASDAQ:DAWN)

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.